COMPASS Pathways Inc.
NASDAQ: CMPS
Company Overview
COMPASS Pathways plc is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health.
The company's focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The team is pioneering the development of a new model of psilocybin therapy, in which their proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support.
COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA), for treatment-resistant depression (TRD), and the company is currently conducting a phase IIb clinical trial of psilocybin therapy for TRD, in 20 sites across Europe and North America.
The company is headquartered in London, UK, with offices in New York, USA.
The company's focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The team is pioneering the development of a new model of psilocybin therapy, in which their proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support.
COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA), for treatment-resistant depression (TRD), and the company is currently conducting a phase IIb clinical trial of psilocybin therapy for TRD, in 20 sites across Europe and North America.
The company is headquartered in London, UK, with offices in New York, USA.
Financial Highlights
$0
Revenue (ttm)
$0
Gross Profit (ttm)
-$4.87
Diluted EPS (ttm)
Management Team
Key Highlights
Market Capitalization
$1,586,775,040
Shares Outstanding
34,805,331
Shares Short (% of Float)
947,323 (0%)
Insider Ownership
0%